Palmitoylethanolamide (PEA) is an endogenous fatty-acid amide that the body produces from lipids and that also occurs naturally in foods. Its biology, including interactions with the nuclear receptor PPAR-α and with inflammatory signalling pathways, has prompted researchers to ask whether PEA has any measurable role in the context of physical exercise, muscle soreness and recovery. For sports-nutrition and supplement formulators, it is useful to understand what the published literature has actually set out to measure and what it has reported, rather than what marketing narratives sometimes imply. This article summarises, strictly and with attribution, a small and emerging body of human and mechanistic studies. It makes no claim that PEA improves recovery, performance or soreness; it reports only study designs and authors’ stated findings.
Why researchers connect PEA to exercise
The rationale that appears in the exercise literature is biochemical rather than clinical. PEA belongs to the N-acylethanolamine family of lipid mediators that are involved in the body’s regulation of inflammatory and pain-signalling processes. Because unaccustomed or eccentric exercise produces a transient inflammatory response and a cluster of symptoms often described as delayed-onset muscle soreness (DOMS), investigators have hypothesised that a lipid mediator with this biology could be worth studying in an exercise setting. A broader systematic review and meta-analysis of double-blind randomised controlled trials examined PEA in the separate context of chronic pain and reported pooled effects on pain scores, while explicitly noting that the overall role of PEA remains a subject of ongoing investigation (Lang-Illievich et al., 2023). That review concerns pain populations, not athletes, and is cited here only to indicate why the molecule attracted research attention; it does not establish any exercise-related outcome.
An early placebo-controlled recovery study
One of the first human studies to place PEA specifically in an exercise-recovery design was a double-blind, randomised, placebo-controlled trial in 28 healthy young men (Mallard et al., 2020). Participants completed a repeated leg-press protocol after taking an oral PEA preparation or placebo. The authors reported lower blood concentrations of myoglobin and lactate at several post-exercise time points in the PEA group compared with placebo, and concluded that PEA supplementation “may aid in muscle recovery” from repeat bouts performed within a short duration. It is important to read this cautiously: the same paper reported that self-rated muscle soreness was consistently higher, not lower, in the treatment group at several time points, and the study was small and industry-supported. The findings describe what was measured in one laboratory under one protocol; they are not a general demonstration that PEA reduces soreness or speeds recovery.
Later controlled studies reporting no functional effect
Subsequent, more tightly controlled work has reported largely null results on functional and symptomatic outcomes. A double-blind, placebo-controlled crossover study in healthy males used a single eccentric-exercise bout to provoke muscle damage (Schouten et al., 2024). The authors reported that, in their protocol, PEA supplementation did not improve muscle soreness, muscle strength or jump performance following the exercise bout, and had no measurable effect on local or systemic markers of muscle damage, catabolism or regeneration. Both conditions showed the expected post-exercise decline in strength and jump height alongside rising creatine kinase, with no separation attributable to the supplement.
A follow-up study from the same research group examined the question at the level of muscle lipid biochemistry rather than performance (Schouten et al., 2026). Participants took PEA or placebo for several days before a muscle-damaging exercise session. The authors reported that PEA supplementation partly modulated the exercise-induced changes in the bioactive lipid profile of skeletal-muscle tissue, attenuating a post-exercise decline in some lipid mediators. Crucially, they also stated that this biochemical shift did not translate into differences in functional outcomes, including muscle strength, explosivity, pain or markers of muscle damage. The authors framed the lipid findings as a mechanistic observation whose practical relevance remains uncertain and in need of further study.
PEA alongside resistance training
A separate strand of research has looked not at acute damage but at longer-term training adaptation. A double-blind randomised controlled trial investigated oral PEA taken during an eight-week resistance-training programme in healthy, recreationally active adults, measuring skeletal-muscle hypertrophy, strength and power (Huschtscha et al., 2024). The authors reported that PEA supplementation did not interfere with the muscle hypertrophy, strength and power gains produced by the training itself. This study is relevant to formulators mainly because it addressed a plausible concern, namely whether a mediator linked to inflammatory signalling might blunt training adaptations in the way that has been debated for some anti-inflammatory agents; within this trial, the authors did not observe such interference. It is not evidence of a performance benefit.
Reading the evidence base as a whole
Taken together, the human studies investigating PEA in an exercise context are few, small in sample size, short in duration and heterogeneous in design, spanning repeated leg-press, single eccentric-exercise bouts and multi-week resistance training. The reported outcomes are mixed: one early trial reported changes in certain blood markers, while later controlled studies reported no clear effect on soreness, strength or functional recovery, and a mechanistic study reported a lipid-profile change without a corresponding functional difference. Several of the studies also carry industry involvement or small numbers of participants, which the authors themselves flag as limitations. The honest summary is that this is an emerging, inconclusive area of investigation rather than a settled one. None of the cited work establishes that PEA improves exercise recovery or athletic performance, and the published authors consistently call for larger, independent trials before any conclusion could be drawn.
Where OptiPEA® fits for formulators
For brands evaluating palmitoylethanolamide as an ingredient, the relevant decision is one of raw-material quality and documentation rather than of finished-product claims. OptiPEA® is a defined, European-manufactured palmitoylethanolamide raw ingredient produced under GMP conditions to a specified purity of at least 99% PEA. It is supplied as a characterised ingredient with accompanying specification documentation, intended for use by qualified product developers. Any health, recovery or performance positioning of a finished product containing PEA is the responsibility of the brand placing that product on the market, and must be substantiated and verified against the permitted claims and regulatory status in each target market. The research summarised above is provided to inform that due-diligence process, not to support any specific claim.
Disclaimer. This article is a factual summary of published scientific research on palmitoylethanolamide (PEA) as a molecule, provided for informational and business-to-business purposes. It is not medical advice and does not constitute a health, therapeutic or efficacy claim for OptiPEA® or any finished product. The regulatory status of PEA and of any associated claims varies by country and market; brands are responsible for verifying the permitted status and claims in their own market with qualified regulatory and medical experts. Always consult a healthcare professional regarding any health condition.
